3 days ago · Montreal, Quebec and Cambridge, UK February 19, 2025: Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify Cryptigen TM tumor-specific antigens (TSAs) in an undisclosed solid tumor.

3 days ago · Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.

2 days ago · Facing the 2028 loss of exclusivity for its cancer blockbuster Keytruda, Merck continued to expand its pipeline Wednesday, announcing a pact with Epitopea to identify “hidden” tumor antigens in an undisclosed solid tumor.. The deal has Merck paying an undisclosed up-front amount to Epitopea, with milestone payments of up to …

2 days ago · MONTREAL and CAMBRIDGE, United Kingdom, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify Cryptigen™ tumor-specific antigens (TSAs) in an undisclosed solid ...

3 days ago · Epitopea was founded in 2021 with sister companies based in Cambridge, UK and in Montreal, Canada. For additional information, please visit www.epitopea.com and follow us on LinkedIn .

2 days ago · Epitopea has entered into a license and research collaboration agreement with Merck to identify Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor. According to the company, non-mutated TSAs are discovered through its CryptoMap platform, revealing aberrantly expressed antigens derived from what is considered to be “junk ...

3 days ago · Montreal, Quebec and Cambridge, UK February 19, 2025: Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, announces a license and research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify Cryptigen TM tumor-specific antigens (TSAs) in an undisclosed solid tumor.

3 days ago · Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co to identify Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor.

3 days ago · Epitopea recently moved its Cambridge HQ to the Babraham Research Campus and is a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies. MSD is the trade name of Merck & Co., Inc., based in New Jersey.

2 days ago · Epitopea Ltd. has signed a license and research collaboration agreement with MSD (Merck & Co. Inc.) to identify Cryptigen tumor-specific antigens in an undisclosed solid tumor. Cryptigen TSAs are shared, nonmutated, aberrantly expressed antigens that are derived from what were thought to be noncoding regions of the genome.